prulifloxacin has been researched along with s 8932 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Hussain, W; Kousar, K; Majeed, A; Rasool, N; Yasmin, F | 1 |
2 other study(ies) available for prulifloxacin and s 8932
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; China; COVID-19; COVID-19 Drug Treatment; Dioxolanes; Fluoroquinolones; Humans; Methyltransferases; Molecular Docking Simulation; Nelfinavir; Phytochemicals; Piperazines; Protein Conformation; RNA Helicases; SARS-CoV-2; Topoisomerase II Inhibitors; Viral Nonstructural Proteins | 2020 |